The Food and Drug Administration (FDA) has approved Abbott’s NeuroSphere Virtual Clinic, a neuromodulation technology that allows health care providers to communicate with patients and adjust treatment settings remotely as needed.

The NeuroSphere Virtual Clinic uses a secure in-app video chat and an integrated remote programming feature (available in the Abbott patient controller app) that allows for therapy optimization in patients who do not live close to a health care provider, have difficulty accessing care, or are unable to go to their physician due to circumstances such as the coronavirus disease 2019 (COVID-19) pandemic. Using the programmer app, clinicians are able to remotely prescribe new treatment settings to the patient’s neuromodulation device via cloud and Bluetooth-based technology. 

The NeuroSphere Virtual Clinic is compatible with the following Abbott neuromodulation technologies:

  • Infinity Deep Brain Stimulation (DBS) System for patients with Parkinson disease and essential tremors;
  • Proclaim™ XR SCS System for patients living with chronic pain of the trunk and/or limbs;
  • Proclaim DRG Neurostimulation System for patients with chronic pain in the lower limbs caused by complex regional pain syndrome or causalgia.

Commenting on the new patient care technology, Keith Boettiger, vice president, Neuromodulation, Abbott, said: “We are continuing to make these kinds of investments and working with regulatory authorities to make these telehealth changes permanent, as we believe that patients should be able to receive the care they need, regardless of whether they can make it physically to the doctor’s office.”


Abbott introduces NeuroSphere™ Virtual Clinic, first-of-its-kind remote neuromodulation patient-care technology in the U.S. [press release]. Abbott Park, IL: Abbott; March 8, 2021.